NEW YORK (GenomeWeb) – The US Food and Drug Administration announced it has approved Abbott Laboratories' companion diagnostic for identifying acute myeloid leukemia patients who have IDH2 gene mutations, and who could benefit from treatment with a new Celgene therapy called Idhifa.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.